Myriad Genetics
Myriad Genetics is a publicly traded molecular diagnostics company developing genetic tests across oncology, reproductive health, and psychiatric genomics, serving oncologists, OB/GYNs, urologists, PCPs, and psychiatrists via an enterprise field sales model and EMR-integrated ordering.
- Company typePublic
- Founded1991
- HeadquartersSalt Lake City, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Myriad Genetics does
Myriad Genetics (NASDAQ: MYGN), founded in 1991 and headquartered in Salt Lake City, Utah, is a publicly traded molecular diagnostics company that discovers, develops, and commercializes genetic tests across three business segments: Oncology, Reproductive Health, and Psychiatric Genomics. The company serves a distributed base of U.S. healthcare providers — oncologists, OB/GYNs, urologists, primary care physicians, and psychiatrists — through an enterprise field sales organization supplemented by direct-to-consumer ordering options and EMR integrations with Epic Aura, Flatiron OncoEMR, athena, eClinicalWorks, and NextGen-Office.
The core technology platform combines next-generation sequencing, whole-genome sequencing, and circulating tumor DNA analysis to deliver an extensive test catalog: MyRisk (63-gene hereditary cancer panel with RiskScore), BRACAnalysis CDx and MyChoice CDx (FDA-approved companion diagnostics), Precise Tumor (500+ gene profiling), Precise MRD (ultrasensitive ctDNA monitoring at 1.45 ppm LOD), Prolaris + AI (genomics plus PATHOMIQ digital pathology), GeneSight (pharmacogenomics), and the reproductive health suite (Prequel, Foresight, FirstGene, SneakPeek). Patent portfolio spans BRCA1/2, newly granted MRD IP, and recent EU Unified Patent Court wins.
Revenue is generated on a per-test basis, with most tests covered by commercial and federally funded insurance and a Myriad Financial Assistance Program covering 58% of eligible patients. The company reported FY2025 revenue of $824.5M with FY2026 guidance of $860-880M. Distribution mixes direct U.S. field sales with international channel partnerships (Zydus Lifesciences for India) and biopharma companion diagnostic collaborations.
Myriad Genetics firmographics
Firmographics- Name
- Myriad Genetics
- Legal name
- Myriad Genetics, Inc.
- Website
- https://myriad.com
- Company type
- Public
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Myriad Genetics is a publicly traded molecular diagnostics company developing genetic tests across oncology, reproductive health, and psychiatric genomics, serving oncologists, OB/GYNs, urologists, PCPs, and psychiatrists via an enterprise field sales model and EMR-integrated ordering.
- Ownership category
- akta.pro rank
Myriad Genetics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Population Genomics & Preventive Precision Health Programs (HLAAANAL), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Myriad Genetics is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Myriad Genetics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Hereditary Cancer Testing: Core testing franchise delivering hereditary cancer risk assessment across 63 genes and 11 cancer types, including MyRisk and BRACAnalysis CDx tests. Volume-driven with 14% volume growth in hereditary cancer testing reported in Q1 2026.
- Reproductive Health Testing: Prenatal screening (Prequel, FirstGene) and carrier screening (Foresight) products generating revenue per test. Facing headwinds with prenatal revenue declining 15% year-over-year.
- Psychiatric Genomics / GeneSight: Pharmacogenomic mental health test generating revenue per test, with 24% revenue growth in Q1 2026. Faces reimbursement headwinds from UnitedHealthcare coverage discontinuation.
- Precise MRD / Oncology: Molecular residual disease testing and tumor genomic profiling (Precise Tumor, MyChoice CDx, Prolaris) representing the company's growth driver, with breast cancer MRD launched commercially in March 2026.
- Credit Facilities / Financing: $200 million credit facility secured with OrbiMed (healthcare investment firm) including $125 million funded capital and an option for additional $75 million, replacing prior financing arrangement.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Myriad Financial Assistance Program (MFAP) - Income-based sliding scale |
| Other | Pay-as-you-go | Insurance-covered testing (standard) |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels11 records
Myriad Genetics product offering
Product offeringCore offering
Myriad Genetics is a molecular diagnostics company that develops and commercializes genetic and genomic tests across oncology, reproductive health, urology, and mental health. The company analyzes patient DNA samples in its laboratories and delivers clinical reports that inform hereditary cancer risk, tumor profiling, companion diagnostic selection, molecular residual disease (MRD) monitoring, pharmacogenomic drug response, and prenatal screening. Its products are ordered predominantly by healthcare providers and reimbursed through insurance or paid for via direct-to-consumer channels.
Product overview
Myriad Genetics operates a multi-segment molecular diagnostics and precision medicine platform with four core product categories: Oncology (Precise MRD, MyRisk, MyChoice CDx, BRACAnalysis CDx, Precise Tumor, Prolaris + AI, FOLR1/FRA), Reproductive Health (Foresight, Prequel, FirstGene, SneakPeek), Mental Health (GeneSight), and Urology (Prolaris + AI, MyRisk). The portfolio spans hereditary cancer risk assessment, tumor genomic profiling, molecular residual disease monitoring, carrier screening, prenatal screening, and pharmacogenomics, offering both standalone tests and integrated workflow solutions. EMR integrations with Epic, Flatiron Health OncoEMR, athena, eCW, and NextGen-Office enable streamlined ordering and consolidated results reporting.
Differentiator
Problem solved
Functional benefit
Brands
- MyRisk: Hereditary cancer risk test evaluating 63 genes associated with 11 hereditary cancers, includes RiskScore for breast cancer risk assessment
- Prolaris
- GeneSight
- Prequel
- Foresight
- MyChoice CDx
- Precise Tumor
- Precise MRD
- BRACAnalysis CDx
- SneakPeek
- FirstGene
Products and services
- MyRisk Hereditary Cancer Test
Quantifiable outcome
- Precise MRD achieved 100% specificity in predicting complete treatment response in breast cancer patients (MONITOR-Breast study)
- +6 more outcomes
Companies that use Myriad Genetics
Customer profileNamed customers1 record
Segments6 records
Ideal customer profiles6 records
Myriad Genetics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability8 records
Feature5 records
Myriad Genetics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- CelLBxHealthminorCelLBxHealth's Parsortix platform pivoting toward partnership-led commercialization with validated early collaborations including Myriad Genetics, AstraZeneca, AdventHealth, and Royal Marsden. Cavendish analyst note identifies Myriad as a validated collaboration partner in CelLBxHealth's commercial strategy.
- PATHOMIQ AIcoreMyriad developed Prolaris + AI, the first prostate cancer biomarker test combining clinical-pathological features, a molecular score, and AI-powered digital pathology technology through partnership with PATHOMIQ AI. The AI-GUR score predicts Gleason score upgrade at follow-up biopsy and is validated in a study of 1,294 patients.
- QIAGENminorQIAGEN and Myriad Genetics developed new QIAseq research panels for homologous recombination deficiency (HRD) research, designed for use with Element Biosciences' AVITI platform. QIAGEN introduced the QIAGEN Discovery Platform, an AI-grounding solution for drug discovery research, showcasing the partnership at AACR 2026.
- Clairity and MagViewminorStrategic collaboration to integrate AI-powered breast cancer risk assessment tools with Myriad's existing hereditary cancer testing platform, enhancing comprehensive breast cancer risk assessment capabilities in the U.S. market.
- Zydus LifesciencescoreZydus Lifesciences signed an agreement to exclusively commercialize three Myriad Genetics cancer tests (BRACAnalysis, MyRisk, MyChoice) in India. This partnership expands Myriad's geographic footprint in one of the world's largest pharmaceutical markets and represents a key international growth initiative.
- EpiccoreMyriad offers native bidirectional EMR integration with Epic through the Epic Aura founding member network. Epic-certified analysts guide adoption, and Myriad provides Variant-Level Data for Epic Genomics and VCF data for research needs.
- Intermountain Precision Genomics (IPG)coreMyriad Genetics acquired assets from Intermountain Precision Genomics in February 2024, strengthening its portfolio with IPG's tumor and liquid biopsy testing services and CLIA-certified laboratory in Utah. This acquisition enhances Myriad's tumor-profiling and precision oncology testing capabilities.
- Flatiron Health (OncoEMR)coreMyriad partnered with Flatiron Health to provide integration to OncoEMR for streamlined end-to-end workflow for germline testing. Clinicians have access to results at point-of-care, facilitating personalized treatment decisions while reducing administrative burden.
Scale indicators14 records
Recent moves6 records
Expansion highlights6 records
Myriad Genetics competitors and assessment
Company assessmentDirect peers
- Natera: Natera is a direct competitor across reproductive health (Panorama NIPT, Vistara carrier/PRS), hereditary cancer (Empower genetics), and most importantly Signatera tumor-informed MRD — the primary head-to-head competitor to Myriad's Precise MRD.
- Guardant Health: Guardant competes directly with Precise Tumor (Guardant360 CDx), Precise MRD (Guardant Reveal), and offers Shield for CRC screening — overlapping in liquid biopsy, comprehensive genomic profiling, and MRD monitoring with similar biopharma and provider channels.
- Veracyte: Veracyte is a genomic diagnostics competitor across urologic oncology (Decipher Prostate, closely comparable to Prolaris + AI), Afirma thyroid, and HRD/MRD initiatives; it has also hired away Myriad's former CTO, making it a strategic technology and talent competitor.
- NeoGenomics: NeoGenomics is a direct peer in oncology testing services, offering comprehensive tumor profiling (RaDaR MRD), hereditary cancer, and pharma/CDx services with overlapping oncologist and biopharma customers across the U.S.
- Exact Sciences: Exact Sciences operates an integrated molecular diagnostics platform (Cologuard, Oncotype DX, Riskguard hereditary cancer, OncoExTra tumor profiling) overlapping directly with Myriad's hereditary cancer, oncology, and risk-assessment franchises.
- Tempus AI: Tempus AI offers NGS tumor profiling, MRD (xF), hereditary testing, and an AI/data platform that mirrors Myriad's emerging AI-diagnostic strategy; it competes for biopharma companion diagnostic and trial-enrichment partnerships.
- Caris Life Sciences: Caris offers MI Profile (comprehensive tumor profiling), MI Cancer Seek (multi-cancer screening with FDA breakthrough designation), and Caris Assure MRD — directly overlapping with Precise Tumor, Precise MRD, and biopharma CDx offerings.
Broad incumbents
- Foundation Medicine (Roche): Foundation Medicine's FoundationOne CDx and FoundationOne Liquid CDx are entrenched comprehensive tumor profiling and CDx products across oncology indications, broadly overlapping with Precise Tumor and MyChoice CDx within pharma and academic oncology.
Emerging players
- Invitae: Invitae competes in hereditary cancer, reproductive health (carrier/NIPT via Prelude), and pharmacogenomics — overlapping substantially with Myriad's genetic testing franchises though currently in financial restructuring, weakening competitive intensity in the near term.
- SOPHiA GENETICS: SOPHiA GENETICS is both a Myriad partner (biomarker validation, CDx development) and a competitor in AI-powered genomics analytics and hereditary/oncology NGS testing across European and global hospital systems.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Myriad Genetics social profiles
Digital presenceMyriad Genetics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Myriad Genetics leadership team
Management profileNumber of profiles
Profiles5 records
Myriad Genetics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Myriad Genetics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Myriad Genetics M&A and investment
M&A and investmentM&A8 records
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Myriad Genetics
What does Myriad Genetics do?
Myriad Genetics is a molecular diagnostics company that develops and commercializes genetic and genomic tests across oncology, reproductive health, urology, and mental health. The company analyzes patient DNA samples in its laboratories and delivers clinical reports that inform hereditary cancer risk, tumor profiling, companion diagnostic selection, molecular residual disease (MRD) monitoring, pharmacogenomic drug response, and prenatal screening. Its products are ordered predominantly by healthcare providers and reimbursed through insurance or paid for via direct-to-consumer channels.
Is Myriad Genetics a public or private company?
Myriad Genetics is a public company. It is classified as public and is currently operating.
When was Myriad Genetics founded?
Myriad Genetics was founded in 1991. It employs 1,001 to 5,000 people.
Where is Myriad Genetics based?
Myriad Genetics is headquartered in Salt Lake City, United States, in the North America region.
How does Myriad Genetics make money?
Five revenue lines are on record. Hereditary Cancer Testing is the primary driver. The others are reproductive Health Testing, psychiatric Genomics / GeneSight, precise MRD / Oncology and credit Facilities / Financing.
Who are Myriad Genetics's main competitors?
Direct peers on record are Natera, Guardant Health, Veracyte, NeoGenomics, Exact Sciences, Tempus AI and Caris Life Sciences. Foundation Medicine (Roche) is listed as a broad incumbent. Emerging players are Invitae and SOPHiA GENETICS.
Does Myriad Genetics have an API?
No public API is recorded for Myriad Genetics.
What industry is Myriad Genetics in?
Myriad Genetics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 621511 and its SIC code is 8071.